Back to today’s briefing

Story perspectives

Justice Department Clears Cassava, Shifts Focus to Epilepsy

2/19/2026

49 9 Full Breakdown

Summary

Story summary

On February 19, 2026, Cassava Sciences announced that the United States Department of Justice has concluded its investigation into simufilam research misconduct.
The indictment against Hoau-Yan Wang, former adviser, has been dismissed.
Cassava halted Alzheimer's development of simufilam last year due to poor trial results.
The company is now shifting its focus to developing simufilam for tuberous sclerosis complex-related epilepsy.

1 of 1

Story summary

On February 19, 2026, Cassava Sciences announced that the United States Department of Justice has concluded its investigation into simufilam research misconduct.
The indictment against Hoau-Yan Wang, former adviser, has been dismissed.
Cassava halted Alzheimer's development of simufilam last year due to poor trial results.
The company is now shifting its focus to developing simufilam for tuberous sclerosis complex-related epilepsy.